Side-by-side · Research reference
BPC-157vsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed9/53 cited
BHuman-MechanisticDraft12/39 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
BPC-157
Semax
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
No known endogenous receptor; mechanism still under investigation
—
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
Semax
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
200–600 mcg / dose intranasalKaplan 2017
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
2–3× per day during cognitive demand
Lower / starter dose
200 mcg / day
Conservative starter for new users.
100 mcg / dose
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Human-mechanistic + Russian clinicalKaplan 2017
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
10–14 day cycles, repeated PRN
Reconstitution
Bacteriostatic water, 1–2 mL
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Morning + early afternoon
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
Short plasma; CNS effect lasts ~3–6 hr
04Side Effects & Safety
Parameter
BPC-157
Semax
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid
Long-term safety
Unknown beyond Phase 2 trial duration
Limited Western RCT data
Drug interactions
None established
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
BPC-157
Semax
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Refrigerate after reconstitution; light-protected.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation